

ASX Announcement

8 December 2020

Receipt of R&D Tax Incentive payment

Antisense Therapeutics Limited ("ANP" or "the Company") would like to advise that the Company has received from the Australian Taxation Office an R&D Tax Incentive refund payment of \$650,603 for the 30 June 2020 financial year. The amount received was in relation to expenditure incurred on eligible R&D activities, including the successful ATL1102 Phase II clinical trial in Duchenne muscular dystrophy. The payment further strengthens the Company's balance sheet following the recently completed \$8.5 million capital raising.

This announcement has been authorised for release by the Managing Director.

Antisense Therapeutics

Mark Diamond
Managing Director
+61 (0)3 9827 8999
www.antisense.com.au

Investment Enquiries

Gennadi Koutchin
XEC Partners
gkoutchin@xecpartners.com.au
1300 932 037

About Antisense Therapeutics Limited (ASX:ANP | US OTC:ATHJY | FSE: AWY) is an Australian publicly listed biotechnology company, developing and commercializing antisense pharmaceuticals for large unmet markets in rare diseases. The products are in-licensed from Ionis Pharmaceuticals Inc. (NASDAQ: IONS), an established leader in antisense drug development. The Company is developing ATL1102, an antisense inhibitor of the CD49d receptor, for Duchenne muscular dystrophy (DMD) patients and recently reported highly promising Phase II trial results. ATL1102 has also successfully completed a Phase II efficacy and safety trial, significantly reducing the number of brain lesions in patients with relapsing-remitting multiple sclerosis (RRMS). The Company has a second drug, ATL1103 designed to block GHr production that successfully reduced blood IGF-I levels in Phase II clinical trials in patients with the growth disorder acromegaly.